Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
563 stopped studies mapped to Malignant Pancreatic Neoplasm and descendants · 93% state a reason
Over the 563 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03623464 | RCT of Mobile Apps & FitBit v. Usual Care | N/A | suspended | Aug 9, 2018 | Weill Medical College of Cornell University | Study is paused for interim analysis. | Efficacy / futility |
| NCT06882746 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon,… | Phase 1 | terminated | Mar 19, 2025 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | suspended | Nov 20, 2020 | Persephone Biosciences | Currently no funding to continue study. | Funding |
| NCT05041335 | Wet Heparinized Suction for Abdominal Cancer(EUS Heparin) | N/A | withdrawn | Sep 13, 2021 | H. Lee Moffitt Cancer Center and Research Institute | study no longer proceeding | Other (stated, no rule matched) |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase 2 | suspended | Oct 1, 2019 | Thomas Jefferson University | Protocol is with FDA review, waiting for funding to be released | Funding |
| NCT05685602 | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic… | Phase 1 | suspended | Jan 17, 2023 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT06487377 | IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced… | Phase 1 | withdrawn | Jul 5, 2024 | Shanghai Pudong Hospital | Study was stopped Sponsor discretion. No patients were dosed. | Other (stated, no rule matched) |
| NCT05438667 | TCR-T Cell Therapy on Advanced Solid Tumors | Early Phase 1 | terminated | Jun 30, 2022 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | In light of the impending acquisition of the project partner, Shanghai Bintie Biotechnology Co.,… | Sponsor / business decision |
| NCT07488884 | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept,…(ResQ108B-PANC) | Phase 1 | withdrawn | Mar 23, 2026 | ImmunityBio, Inc. | The sponsor has changed the development plans which is not for safety reasons. | Safety / toxicity |
| NCT06091930 | A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in… | Phase 1 | terminated | Oct 23, 2023 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT05494697 | Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With… | Phase 2 | suspended | Aug 10, 2022 | AIM ImmunoTech Inc. | A business decision to place screening/enrollment on hold. Study redesign/amendment pending… | Enrollment / accrual |
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | Phase 2 | terminated | Mar 18, 2022 | National Cancer Institute (NCI) | The study was terminated due to low accrual and insufficient efficacy seen in first few… | Efficacy / futility |
| NCT04007640 | Early Screening of Pancreatic Lesions : Development of New Imaging Tools(PAIR-PANCREAS) | N/A | terminated | Jul 5, 2019 | Assistance Publique - Hôpitaux de Paris | Population difficult to recruit; number of enrolled patients sufficient for analyses. | Enrollment / accrual |
| NCT05737615 | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal,… | Phase 1 | withdrawn | Feb 21, 2023 | Memorial Sloan Kettering Cancer Center | Study tracer is currently unavailable | Other (stated, no rule matched) |
| NCT04123574 | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | Early Phase 1 | withdrawn | Oct 11, 2019 | BioXcel Therapeutics Inc | No longer relevant to field | Other (stated, no rule matched) |
| NCT07377526 | TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer | Phase 1 / Phase 2 | suspended | Jan 30, 2026 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT06528093 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With… | Phase 1 | terminated | Jul 30, 2024 | Boehringer Ingelheim | not stated | Not stated |
| NCT04469504 | Preoperative Prehabilitation for Sarcopenic Patients Prior to Pancreatic Surgery for…(PSOAS) | N/A | terminated | Jul 14, 2020 | University Hospital, Lille | The study was terminated prematurely due to patient inclusion difficulties. | Other (stated, no rule matched) |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | Phase 1 / Phase 2 | withdrawn | Apr 16, 2020 | Chongqing Precision Biotech Co., Ltd | The sponsor requested to terminate the study. | Other (stated, no rule matched) |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT00640978 | Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic… | Phase 2 | terminated | Mar 21, 2008 | M.D. Anderson Cancer Center | Significant Adverse Effects - Futility | Safety / toxicity |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Phase 1 | terminated | Jun 20, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT04809766 | Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic… | Phase 1 | terminated | Mar 22, 2021 | Fred Hutchinson Cancer Center | Study terminated due to end of funding. | Funding |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for… | Phase 2 | terminated | Jul 23, 2021 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT04158635 | Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic… | Phase 1 | suspended | Nov 12, 2019 | City of Hope Medical Center | Accrual Goal met | Enrollment / accrual |
| NCT05419479 | Switch Maintenance in Pancreatic | Phase 1 / Phase 2 | suspended | Jun 15, 2022 | James Cleary, MD, PhD | Efficacy concerns. | Efficacy / futility |
| NCT05275075 | Identify microRNAs in Cachexia in Pancreatic Carcinoma(SCC-miRPanCa) | — | terminated | Mar 11, 2022 | University of Oklahoma | Translational scientist left university | Other (stated, no rule matched) |
| NCT04975217 | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | Early Phase 1 | suspended | Jul 23, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor… | Phase 1 / Phase 2 | terminated | Nov 19, 2018 | National Cancer Institute (NCI) | Study was closed due to lack of accrual and study outcomes overlapped with another protocol's… | Enrollment / accrual |
| NCT05911243 | Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV… | N/A | terminated | Jun 20, 2023 | University of Washington | Study closed per SRC Low Accrual Policy. | Enrollment / accrual |
| NCT03825289 | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer(THREAD) | Phase 1 | terminated | Jan 31, 2019 | University of Utah | Lack of Funding | Funding |
| NCT05415917 | Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer… | Phase 2 | withdrawn | Jun 13, 2022 | Rutgers, The State University of New Jersey | No patients enrolled | Enrollment / accrual |
| NCT06653192 | EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction… | N/A | suspended | Oct 22, 2024 | Hospital Universitari de Bellvitge | Class I Recall (Feb 2026): Boston Scientific issued a global recall for specific lots of AXIOS… | Other (stated, no rule matched) |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2023 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT02072616 | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.(CTC-Pancreas) | N/A | terminated | Feb 26, 2014 | University Hospital, Rouen | Analysis not possible at the stage | Other (stated, no rule matched) |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or… | Phase 2 | withdrawn | Jul 22, 2020 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT07173374 | Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A…(SCART-P) | Phase 1 | suspended | Sep 15, 2025 | Shandong Cancer Hospital and Institute | The study was terminated early due to slow patient accrual. Enrollment was substantially lower than… | Enrollment / accrual |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers… | Phase 1 / Phase 2 | terminated | May 13, 2020 | University of Southern California | Study drug no longer available | Other (stated, no rule matched) |
| NCT02872831 | Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle | N/A | withdrawn | Aug 19, 2016 | Thomas Jefferson University | Principal Investigator let the institution prior to study initiation. | Investigator |
| NCT05518110 | PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With…(PaTcH) | Phase 2 | terminated | Aug 26, 2022 | Cancer Trials Ireland | Study terminated due to futility | Efficacy / futility |
| NCT05188573 | EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset… | N/A | withdrawn | Jan 12, 2022 | ClearNote Health | Study not initiated. | Other (stated, no rule matched) |
| NCT05131776 | EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma. | Phase 2 / Phase 3 | terminated | Nov 23, 2021 | Chinese University of Hong Kong | Inadequate funding | Funding |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and…(ALAFOSS-01) | Phase 1 | terminated | Sep 19, 2024 | AstraZeneca | The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01… | Enrollment / accrual |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary… | Phase 2 | terminated | Dec 24, 2018 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT05442749 | Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic…(PARPi-PANC) | Phase 2 | terminated | Jul 5, 2022 | Centre Leon Berard | Study not feasible, patient accrual rate too low. | Enrollment / accrual |
| NCT03065062 | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR… | Phase 1 | suspended | Feb 27, 2017 | Dana-Farber Cancer Institute | Funding and drug supply to continue the study are pending. | Drug supply |
| NCT05360745 | Quality of Life With Nutritional Supplementation in Patients With Locally…(FOODPANC) | N/A | withdrawn | May 4, 2022 | Fundacion para la Excelencia y la Calidad de la Oncologia | Few months later the site initiation visit, the principal investigator decided not to continue with… | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials